Skip to main content
BICYCLE THERAPEUTICS PLC logo

BICYCLE THERAPEUTICS PLC — Investor Relations & Filings

Ticker · BCYC ISIN · US0887861088 LEI · 213800XKUI6R7GKC3E43 US Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2021-07-08 Director's Dealing
Country GB United Kingdom
Listing US BCYC

About BICYCLE THERAPEUTICS PLC

https://www.bicycletherapeutics.com/

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines known as Bicycle® molecules. These are fully synthetic bicyclic peptides engineered to combine the targeting specificity and pharmacological properties of large molecule biologics with the rapid and deep tissue penetration of small molecules. The company's proprietary platform creates precision-guided therapeutics to address diseases underserved by existing treatments. The primary focus of its development pipeline is in oncology, with a portfolio of candidates designed to target solid tumors. Beyond oncology, Bicycle Therapeutics leverages its technology through collaborations to explore applications in other therapeutic areas, including anti-infectives, cardiovascular diseases, and central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-07-08 English
8-K Filing
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 28, 2021, reporting the submission of matters to a vote of security holders at the company's Annual General Meeting (AGM). It details the voting results on various proposals including director elections, auditor appointments, remuneration reports, and share allotment authorizations. The document focuses exclusively on the voting results from the AGM and does not contain the full AGM materials or presentations, nor does it include financial statements or detailed management discussion. Therefore, it is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6430 characters) and content confirm it is not merely an announcement of a report but the actual voting results report.
2021-06-28 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to a shareholder meeting. It discusses proposals to be voted on at the Annual General Meeting, including share allotment authority and pre-emption rights. The text includes voting instructions and references to the proxy statement and related materials. This type of document is used to solicit shareholder votes and provide information about matters to be decided at the meeting. It is not the Annual Report, nor an earnings release, nor a management report. It is not a report publication announcement since it contains substantive content related to the proxy and voting. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI).
2021-05-27 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a Controlled Equity Offering Sales Agreement and related prospectus supplement for the sale of American Depositary Shares (ADSs). It includes details about the sales agreement, commissions, and legal opinions but does not contain financial statements or detailed financial performance data. The document is an announcement of a capital raising activity rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 6489 characters, sufficient to provide substantive details about the financing event.
2021-05-24 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement and accompanying prospectus related to a shelf registration statement filed with the SEC. It details an offering of American Depositary Shares (ADSs) up to $100 million, including terms of the offering, risk factors, use of proceeds, plan of distribution, and legal matters. The document is a formal offering document used to raise capital through securities issuance. It is not a financial report, earnings release, management discussion, or any other type of report. It is a capital markets document specifically related to financing activities and securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not a brief announcement or regulatory filing. Confidence is high due to clear identification of the document as a prospectus supplement for an equity offering.
2021-05-24 English
FORM 4 SUBMISSION
Director's Dealing
2021-05-10 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.